Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma	Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, esophageal adenocarcinoma	Recruiting	Phase 1 / Phase 2	2026-06-03		NCT07622940

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing Biotech	32

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Peking University Shenzhen Hospital	Shenzhen	China	68

Clinical trials